Amoy Diagnostics Co., Ltd.

Shenzhen Stock Exchange 300685.SZ

Amoy Diagnostics Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2023: 0.03

Amoy Diagnostics Co., Ltd. Debt to Equity Ratio is 0.03 for the year ending December 31, 2023, a -15.35% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Amoy Diagnostics Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2022 was 0.04, a 704.94% change year over year.
Amoy Diagnostics Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2021 was 0.00, a -92.99% change year over year.
Amoy Diagnostics Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2020 was 0.06, a 1,043.01% change year over year.
Amoy Diagnostics Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2019 was 0.01, a -64.15% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Shenzhen Stock Exchange: 300685.SZ

Amoy Diagnostics Co., Ltd.

CEO	Ms. Ying Chen
IPO Date	Aug. 3, 2017
Location	China
Headquarters	39 Dingshan Road
Employees	1,119
Sector	Healthcare
Industries Biotechnology

Description

Amoy Diagnostics Co., Ltd., a diagnostic company, focuses on molecular diagnostics for oncology precision medicine in China and internationally. The company offers NGS, real-time PCR, FISH, and extraction assays. Amoy Diagnostics Co., Ltd. was founded in 2008 and is based in Xiamen, China.

Key trends

Past 5 years